Senses Disorder TRIZ Cases

Anti-integrin alpha8beta1 antibody blocks ligand interaction to resolve the contradiction between functional inhibition and therapeutic availability.

Compounds targeting IDO1 apoprotein before heme incorporation achieve potent inhibition with IC50 values under 200 nM.

A non-irritating ocular composition combines mild surfactants with polyhexamethylene biguanide to clean eyelids effectively.

Mutated hinge regions in asymmetric IgG4 bispecific antibodies prevent dynamic heavy chain exchange, ensuring stable therapeutic efficacy.

Antisense oligonucleotides correct cryptic splice site activation in Ush1c, restoring full-length harmonin protein and sensory function.

Anti-EGFL7 antibodies target EGFL7 to improve anti-angiogenic therapy efficacy.

A biodegradable polymer matrix releases corticosteroids into the eye for over two months through controlled hydrolysis and diffusion.

Formula II compounds inhibit Rho-kinase activity, addressing the lack of selective ROCK2 inhibitors for treating hypertension and neuronal degeneration.

Aqueous IL-6 antagonist formulations maintain IgG2-A isoforms through precise pH optimization and composite buffering.

Buffer-free aflibercept formulations optimize pH and ionic strength to prevent aggregation, ensuring prolonged shelf life for ophthalmic applications.

A dendritic peptide core presents multiple identical B-cell recognition sequences to directly stimulate antibody production.

Targeting peroxidasin activity bypasses VEGF resistance mechanisms, offering a novel pathway for treating abnormal angiogenesis-related diseases.

Deimmunized antibodies bind to the extracellular domain of EphB4, inhibiting angiogenesis and reducing tumor growth in cancers expressing this receptor.

EDTA and tromethamine enhance riboflavin absorption into the corneal stroma, enabling visible light cross-linking without de-epithelization.

Compounds stimulate retinal pigment epithelium cell proliferation and differentiation, reversing damage in dry age-related macular degeneration.

High-dose biotin pharmaceutical compositions deliver therapeutic levels via oral or injectable routes to address visual deficiencies.

Non-ionic surfactants generate negative zeta potential in saturated oils, stabilizing prostaglandins while avoiding corneal lesions from cationic agents.

Heterocyclic modulators inhibit fatty acid synthase, reducing viral production and inducing cancer cell death while minimizing side effects.

Intravitreal methotrexate reduces secondary punctate keratitis and intraocular pressure elevation while improving visual acuity.

Vectors encoding flea allergens induce T regulatory cells, resolving the trade-off between suppressing allergic reactions and maintaining infection resistance.

Epigenetic modulators reactivate OCT4 stemness to expand corneal endothelial cells, resolving donor scarcity for transplantation.

Engineered botulinum neurotoxin receptor binding domain mutations enhance human synaptotagmin II affinity.

Fc-fusion natriuretic peptides extend half-life and treat skeletal dysplasias by activating NPR-B signaling.

Dihydropyrimidin-2-one compounds target the RORγ receptor to block Th17 cell differentiation and reduce IL-17 production in autoimmune diseases.

Astaxanthin derivatives with hydrophilic side chains enhance water solubility and oral absorbability.

Freeze-drying an organic-water drug mixture inhibits crystal growth, maintaining nanoscale size for long-term stability without aggregation.

Deuterated benzopyran compounds act as selective cyclooxygenase-2 inhibitors, reducing gastrointestinal adverse reactions while maintaining analgesic efficacy.

Novel fluorinated benzenesulfonamide derivatives act as targeted carbonic anhydrase inhibitors for pharmaceutical applications.

Stable single domain antibody compositions resolve physical instability and toxicity trade-offs in topical psoriasis treatments.

Re-esterified triglyceride omega-3 supplementation normalizes meibum composition by increasing anti-inflammatory lipid levels.

Inhibiting Toll-like receptor 2 activity reduces severe inflammatory cytokine responses and mortality in Herpes Simplex Virus infections.

Isopropyl myristate mediates prostaglandin FP receptor agonist permeation across the stratum corneum to reduce subcutaneous fat without systemic side effects.

Integrated riboflavin and UVA applicator induces collagen cross-linking to stabilize progressive myopia.

Formula I prostaglandin derivatives reduce aqueous humor production to control intraocular pressure without beta-blocker pulmonary side effects.

Low-dose selective alpha-2 adrenergic receptor agonists target ocular arterioles to induce vasoconstriction and improve cosmetic eye whiteness.

Removing buffering agents prevents chemical reactivity between ketotifen and naphazoline, extending active ingredient stability.

Viral vectors deliver Pou2f2 or Tppp3 polynucleotides to restore retinal ganglion cell axons, countering progressive degeneration in glaucoma.

Orally absorbed lipophilic chelators convert to hydrophilic metabolites, resolving the trade-off between metal clearing efficiency and renal toxicity.

Modified prostaglandin analogs resolve contradictions between therapeutic efficacy and topical comfort via structural parameter changes.

Intramural DHA analogs shield cochlear cells from ototoxic medication damage, preserving hearing and balance function.

Chimeric antigen-presenting cells display membrane-embedded APLNR to generate specific antibodies that overcome structural conservation barriers.

Structural modifications of N-alkyl tryptanthrin derivatives enhance indoleamine 2,3-dioxygenase inhibition to treat metabolic disorders.

Optimized microsphere diameters retain particles in the anterior chamber while preventing inflammation and hyperemia.

Optimized excipient concentrations prevent chemical degradation and physical aggregation, ensuring long-term structural integrity.

Temperature-sensitive elastin-like polypeptide extends C-peptide half-life via controlled release, reducing injection frequency and immune response risks.

A softgel eye health supplement combines zeaxanthin, lutein, and omega-3 oils to support macular density.

Anti-FcRn antibodies bind neonatal Fc receptors to block IgG recycling, reducing pathogenic autoantibodies without glucocorticoid side effects.

Gold nanoparticles and auxiliary ingredients in contact lenses prevent corneal inflammation during extended wear.